Live feed
Filing
SCHEDULE 13D
SCHEDULE 13D0001193125-26-045048·SpyGlass Pharma, Inc.
Schedule 13D ownership disclosure
SpyGlass Pharma, Inc.
Common Stock, par value $0.00001 per share · CUSIP: 85220G109
Event date: 2026-02-09
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Vensana Capital I GP, LLCReported CIK 0001854073
Shares: 3,310,619 · Class: 9.9%
- Vensana Capital I, L.P.Reported CIK 0001757539
Shares: 3,310,619 · Class: 9.9%
- Kirk NielsenReported CIK 0001523522
Shares: 3,312,141 · Class: 9.9%
- Peter Justin KleinReported CIK 0001608710
Shares: 3,310,619 · Class: 9.9%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001193125-26-045048
- Form type
- SCHEDULE 13D
- Filer
- SpyGlass Pharma, Inc.
- CIK
- CIK 1778922
- Filed
- Feb 10, 2026
- Reporting period
- Feb 09, 2026
- Description
- Schedule 13D beneficial ownership